CRC Research Update — June 09, 2026
Today's colorectal cancer research highlights
metastatic
A collection of 148 issues
CRC Research Update — June 07, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 01, 2026
Today's colorectal cancer research highlights
BRAF V600E triplet regimen advances in phase 3 trial
Skip to content
The CRC Digest
BRAF V600E triplet regimen advances in phase 3 trial
BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology)
This content
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases
Skip to content
The CRC Digest
◆ TRIAL DATA
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine
A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.
Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology
A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes
Skip to content
The CRC Digest
▸ TREATMENT
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open
An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study